Capricor Draws Investor Attention As Shareholder Kaos Capital Pushes For Board Shakeup Ahead Of Key FDA Decision On DMD Therapy

Summary

Capricor faces pressure from shareholder Kaos Capital to shake up its board ahead of an upcoming FDA decision on its DMD therapy candidate. The activist campaign highlights investor concerns regarding management and governance.